Pfizer Inc vs Toyota Motor Corp — how do they compare? Pfizer Inc trades at $27.89 (market cap $158.39B), while Toyota Motor Corp trades at $193.77 (market cap $228.43B). The key difference: Toyota Motor Corp is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | TM | |
|---|---|---|
Market Cap | $158.39B | $228.43B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $248.29 |
52-Week Low | $23.60 | $166.50 |
Enterprise Value | $209.89B | $427.29B |
Dividend Yield | 6.19% | 3.27% |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Toyota Motor (TM) trades at $191.45, down 2.87% amid bearish technical signals, though fundamentals remain strong with attractive valuation metrics including a P/E of 8.51 and P/S of 0.74. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $7.57 exceeding estimates by 62%. Recent news highlights strong demand for hybrid models like the RAV4 and strategic partnerships, though tariff threats and a global recall present headwinds.
TM offers value with solid profitability and growth, but faces near-term technical pressure and geopolitical risks. The stock's undervaluation relative to DCF estimates around $342 presents opportunity, yet investors must weigh competitive pressures and macroeconomic uncertainties against the company's operational strength and market leadership in hybrid technology.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →